Overview of IP Group's Share Surge#
IP Group's shares increased by over 8% on Tuesday, following the announcement of a 13% rise in net asset value (NAV) per share for 2025. This boost was largely attributed to the company's involvement with Pfizer Inc.'s acquisition of a weight-loss drugmaker, which is expected to generate substantial income.
Net Asset Value Increase#
The net asset value per share rose to 110.4 pence as of December 31, 2025, up from 97.7 pence the previous year. This increase was driven by £128.2 million in licensing income linked to Pfizer's acquisition of Metsera, a company focused on obesity treatments, for up to $10 billion in November.
Accounting Changes and Challenges#
Despite this positive news, the company faced complications due to a reclassification as an "investment entity" under IFRS 10 accounting standards. This change affected how the company's subsidiaries are reported on its balance sheet and led to a technical breach of covenants related to a £120 million private placement. The breach arose because cash was counted across the group rather than just at the parent company level.
Financial Position and Future Outlook#
At year-end, IP Group reported £87.8 million in cash equivalents and £123.2 million in deposits, but not enough cash was available at the parent level. The company secured a waiver from noteholders and transferred cash to address the issue. Despite a profit of £66.9 million compared to a loss of £207 million in 2024, shares are trading at a 47% discount to the stated NAV. The stock closed 2025 at 58.6 pence, while the NAV stood at 110.4 pence.
Chief Executive Greg Smith expressed confidence in achieving over £250 million in exits between 2025 and the end of 2027. Additionally, IP Group is collaborating with Aberdeen to manage a portfolio of UK venture investments and has set aside £30 million for future shareholder returns.